Behind the Prescription Pad: Why Most American Physicians Decline to Prescribe Ivermectin

For many Americans who have researched ivermectin and believe it may benefit them, the most frustrating obstacle is not a pharmacy counter or a federal regulation — it is their own physician. A growing number of patients report leaving appointments empty-handed after requesting ivermectin, often without receiving a satisfying explanation. To understand why, it is necessary to examine the overlapping pressures that shape physician behavior in the United States today.

Evidence-Based Guidelines and the Role of Medical Societies

American physicians do not practice in a vacuum. The clinical decisions they make are heavily influenced by guidance issued by major professional organizations — the Infectious Diseases Society of America (IDSA), the American College of Physicians, and the National Institutes of Health (NIH), among others. For ivermectin, these bodies have consistently declined to recommend its use for conditions such as COVID-19, citing insufficient or inconclusive evidence from large-scale randomized controlled trials.

The NIH's COVID-19 Treatment Guidelines Panel, for instance, has maintained a "neither for nor against" or outright discouraging stance on ivermectin for viral respiratory illness throughout much of the pandemic period and beyond. When a physician's professional society signals skepticism, most clinicians follow suit — not out of blind deference, but because these guidelines represent a synthesis of available evidence that individual practitioners rarely have time to independently evaluate.

This dynamic creates what some researchers call the "guideline gap": the space between what a patient believes the evidence supports and what institutional medicine has formally endorsed. Patients who have read preprint studies or followed alternative medical commentators may arrive at an appointment with a different evidentiary framework than their physician operates within.

The Liability Equation

Beyond guidelines, liability is a powerful and underappreciated factor. American medicine operates within a litigation-sensitive environment unlike that of many peer nations. When a physician prescribes a medication off-label — meaning for a purpose not formally approved by the Food and Drug Administration — they assume a degree of professional and legal exposure that prescribing within approved indications does not carry.

For ivermectin specifically, the FDA issued explicit public communications advising against its use for COVID-19, including statements that were later the subject of legal scrutiny regarding their scope. Nevertheless, those communications shaped the perception among hospital risk managers and malpractice insurers that ivermectin prescriptions for unapproved uses carried elevated liability risk. Many hospital-employed physicians, in particular, face institutional policies that restrict or prohibit off-label ivermectin prescribing regardless of their personal clinical judgment.

Private practice physicians have somewhat more latitude, but the chilling effect of potential board complaints or malpractice claims remains real. Several physicians who prescribed ivermectin outside approved indications during the pandemic faced state medical board investigations, a development that did not go unnoticed among their colleagues.

What Physicians Are Prescribing Instead

Understanding what physicians prescribe in lieu of ivermectin helps clarify the clinical logic at work. For COVID-19, the current standard-of-care toolkit includes antivirals such as nirmatrelvir-ritonavir (Paxlovid) for high-risk patients, along with supportive care protocols. For post-acute sequelae — what many patients call long COVID — physicians rely on symptom-specific management, rehabilitation referrals, and emerging specialist protocols.

For parasitic infections, which represent ivermectin's FDA-approved territory, physicians do prescribe the drug when indicated. Strongyloidiasis, onchocerciasis, and certain ectoparasite infestations are conditions for which ivermectin remains a standard and appropriate choice. The prescription gap, therefore, is not universal — it is concentrated in the off-label space where evidentiary and liability pressures converge.

For patients seeking alternatives to ivermectin for anti-inflammatory or immune-modulating purposes, physicians may recommend established agents such as low-dose naltrexone (itself an off-label but more widely accepted option), corticosteroids in appropriate contexts, or enrollment in clinical research protocols.

The Physician's Perspective

Infectious disease specialists interviewed for background by this publication described a consistent professional tension. Many acknowledged that ivermectin's safety profile — particularly at standard antiparasitic doses — is well-documented and generally favorable. The reluctance, they emphasized, is not primarily about safety concerns at therapeutic doses, but about the absence of robust efficacy data for the conditions patients most commonly request it for.

"I have no objection to ivermectin as a drug," one specialist noted. "My objection is to prescribing any medication without a credible evidence base for the specific indication. That principle applies equally to ivermectin and to any other compound."

Primary care physicians expressed a different but related concern: time. Evaluating the competing evidence claims around ivermectin — including methodological critiques of both supportive and negative trials — requires hours of careful reading that most practitioners cannot dedicate during a standard clinical workday. Defaulting to major society guidelines is, in this context, a rational if imperfect coping mechanism.

What Patients Can Do

For Americans who believe ivermectin may be appropriate for their situation, several constructive pathways exist. Requesting a referral to an infectious disease specialist for documented parasitic conditions places the conversation in a clinical context where ivermectin prescribing is routine and uncontroversial. For off-label interests, seeking out physicians who practice integrative or functional medicine — and who are accustomed to evidence-based off-label prescribing — may yield more productive consultations.

Patients should approach these conversations prepared with specific clinical questions rather than treatment demands. Physicians respond more favorably to patients who demonstrate genuine engagement with the evidence than to those who arrive with a predetermined conclusion. Understanding the physician's evidentiary and liability concerns, rather than dismissing them, is likely to produce more constructive dialogue.

The prescription gap around ivermectin is real, but it is not monolithic. It reflects a complex interplay of institutional guidelines, legal exposure, evidentiary disputes, and time constraints — forces that shape prescribing decisions across American medicine far beyond this single drug.